Trillium Therapeutics Receives Prestigious National Award
News Jun 14, 2014
Trillium Therapeutics Inc. has announced that it has been awarded BIOTECanada’s 2014 Gold Leaf Award as Early Stage Health Company of the Year.
“We are honored to receive this coveted national award,” remarked Trillium’s Chairman, Dr. Calvin Stiller. “The company had a remarkable year in 2013, culminating in an unprecedented capital raise from premier healthcare funds. This was made possible because of the substantial progress we made in advancing our innovative CD47 checkpoint inhibitor program towards the clinic. It is gratifying to see these accomplishments recognized by the industry.”
“Every single member of the Trillium team has worked very hard to achieve our goals and we all feel rightfully proud of this award from BIOTECanada and our peers,” added Dr. Niclas Stiernholm, President and CEO. “With the outstanding team that we are fortunate to have assembled, we are optimistic that the future of our company is bright.”
Almost 95% of people with early-diagnosed breast cancer will require surgery and it’s often the first line of treatment for people with brain tumors, for example. But despite improvements in surgical techniques over the past decade, the cancer often comes back after the procedure. Now, a team has developed a spray gel embedded with immune-boosting drugs that could help.READ MORE